Commit Biologics has announced the appointment of Janine Schuurman to its Board of Directors. Janine is a widely recognised ...

In a global market marked by volatility, with U.S. stocks mostly lower due to AI competition fears and mixed economic signals from major economies, investors are closely watching the technology sector ...

Learn more about whether AbbVie Inc. or Genmab A/S is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Patients with relapsed or refractory large B-cell lymphoma who received epcoritamab or glofitamab in real-world settings experienced worse outcomes than observed in trials. Higher toxicity rates ...

As we observe World Cancer Day today, let us look at some of the trends in cancer therapeutics expected to improve cancer ...

AbbVie and Genmab’s would-be blockbuster epcoritamab has been recommended for conditional approval in the EU as a treatment for diffuse large B-cell lymphoma (DLBCL), an aggressive form of non ...

Jurrien Timmer, Director of Global Macro at Fidelity Management & Research Company shared his outlook for 2025.

We recently published a list of 12 High Growth International Stocks to Invest in Now. In this article, we are going to take a ...

MP0533 also binds CD3, which is expressed on cytotoxic T-cells and is the principle mechanism of action of approved T-cell engagers like blinatumomab, tarlatamab, epcoritamab, and others.

AbbVie will pay Danish antibody specialist Genmab $750 million upfront for rights to a series of drugs headed by epcoritamab, a bispecific antibody in development for non-Hodgkin’s lymphoma.

Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company ...